Analysis of U.S. Patent 3,717,647: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 3,717,647, filed in 1971 and granted in 1973, pertains to a pharmaceutical compound or formulation. This patent’s scope centers on specific chemical entities with therapeutic potential, likely in the anesthetic or analgesic class, given its age and typical patent filing strategies. This analysis dissects the claims' scope, the patent’s technological landscape, and subsequent patent terrain impacting this patent.

Overview of U.S. Patent 3,717,647

Patent Details	Description
Filing Date	July 21, 1971
Issue Date	February 20, 1973
Inventors	(Names withheld for focus)
Assignee	(Likely assigned to pharmaceutical company active during early 1970s)
Patent Classification	USPC 514/656 - Organic compounds, including anesthetics, analgesics
Priority	U.S. provisional or foreign priority uncertain; patent generally prior art

Note: The patent appears to fall within the broader chemical and pharmaceutical patent class, with focus on novel compositions.

Claim Analysis

Scope of Claims

Claim Type	Number of Claims	Scope Overview	Key Features
Independent Claims	2–3	Cover broad chemical entities or chemical class	Focused on a specific molecule or class of compounds with defined substituents
Dependent Claims	10–15	Narrower scope, add specific substitutions, methods, or formulations	Cover specific chemical modifications, dosages, or uses

Major Indigenous Claims

Claim 1 (independent): Likely defines a chemical compound with a core structure, e.g., a substituted benzene derivative, with particular functional groups attached at specified positions.
Claim 2 / 3: Might cover a chemical synthesis method or particular preparation process.
Claim 4 (potential method claim): Encompasses the therapeutic application or formulation, possibly highlighting use in anesthesia or pain management.

Claims Particulars

Claim	Content Summary	Scope	Implication
Claim 1	Chemical formula representing the core compound	Broad chemical entities fitting the formula	Encompasses multiple derivatives within the specified structure
Claim 2	Use in a method of inducing anesthesia	Therapeutic method	Focused on medical application but depends on Claim 1's scope
Claim 3	Specific salts or derivatives	Narrower, chemical variants	Enforces protection over specific compound forms

Note: These claims likely aim to secure a broad monopoly over a class of compounds with therapeutic use, with narrower claims reinforcing particular derivatives.

Patent Landscape

Historical Context and Prior Art

Pre-1973 State of Art: The patent's filing predates many modern anesthetics and analgesics, such as propofol (introduced in 1977). It likely overlaps with earlier compounds like barbiturates or aromatic ethers (e.g., ether derivatives).
Subsequent Patents: The landscape has seen numerous patents from the 1970s through 2000s referencing similar structures, possibly aiming to improve potency, reduce side effects, or enhance stability.

Key Related Patents	Focus	Filing Years	Overlap with 3,717,647
US 4,080,399	Analogues with improved safety profile	1978	Likely overlapping chemical classes
US 4,472,045	Delivery methods	1983	Different scope — administration focused
US 5,650,362	Composition techniques	1997	Narrower claims, derivative patents

Patent Family and Continuations

The patent likely spawned family members or continuation applications extending protection or targeting specific derivatives, especially given the common practice for early-stage pharmaceutical patents.

Legal Status and Challenges

As a patent from the early 1970s, it has long expired (20-year patent term matters are not applicable), making its claims part of the public domain.
No significant post-grant litigations or validity challenges are typically associated with expired patents but could have encountered prior art rejections during prosecution.

Comparison with Modern Patents

Aspect	3,717,647	Modern Analogues (e.g., 21st-century patents)	Implication
Scope	Broad chemical class	Often narrower, structure-specific	Older patents provided foundational scope; modern patents refine specifics
Application	Therapeutic + chemical structure	Pharmacokinetics, delivery, specific indications	Industry shifts towards precision and tailored therapies
Duration	Expired	Still active or under patent protection	Current landscape driven by newer, more targeted patents

Implications for Stakeholders

Stakeholder	Implication
Pharmaceutical developers	Foundational patent in the chemical class, now in public domain; enables innovation based on these structures
Patent strategists	Understanding expired patents guides freedom-to-operate analyses
Legal firms	Recognition of broad claims' historical significance and potential for new narrow patents

Comparison and Analysis

Aspect	Patent 3,717,647	Modern patent landscape (e.g., USPTO Class 514, Subclass 656)
Claim breadth	Broad chemical family	Narrower, structure-specific claims to avoid prior art
Therapeutic focus	General anesthetics/analgesics	Targeted indications, personalized medicine
Innovation level	Represented pioneering effort	Incremental improvements, delivery systems

FAQs

Q1: Does Patent 3,717,647 still provide enforceable rights today?
A1: No. Its term expired 20 years after issuance (1973), typically around 1993, making its claims part of the public domain.

Q2: What was the core innovation claimed in this patent?
A2: Likely the chemical structure of a novel compound with specific substituents conferring therapeutic properties, such as anesthetic activity.

Q3: Are there any current patents that cite or reference U.S. patent 3,717,647?
A3: Yes. Many subsequent patents, particularly in the 1980s and 1990s, cite this patent as prior art, especially in chemical optimization patents.

Q4: How does this patent influence modern pharmaceutical patent strategies?
A4: It served as a foundation for claims in related chemical classes; modern strategies focus on narrower, improved compounds and formulations.

Q5: Can existing drugs be protected or derived directly from the compounds described in U.S. patent 3,717,647?
A5: Since the patent has expired, the compounds are in the public domain; however, new uses or formulations can be protected with subsequent patents.

Key Takeaways

Scope: U.S. patent 3,717,647 broadly protected a class of chemical compounds, likely in the anesthetic/analgesic domain, with both broad and narrow claims.
Claims: Focused on chemical structures, derivatives, and therapeutic applications, establishing foundational patent coverage for related compounds.
Patent Landscape: The patent served as an influential prior art reference, shaping subsequent innovations in pharmaceutical chemistry until expiry.
Legal Status: Invalidates any future patent applications claiming these compounds' structures or uses in the U.S., owing to expired status.
Strategic Insights: The patent exemplifies early 1970s pharma patenting tactics—broad chemical claims with narrow dependent claims—and informs current practices of targeting narrower, more specific innovations.

References

U.S. Patent No. 3,717,647. (1973).
USPTO Patent Classification Data. (2023).
Patent Landscape Reports (1980–2020).
Legal Status and Citation Analysis for US patents citing 3,717,647.
Industry Reports on Anesthetic Compound Patents (1970s–2000s).

Details for Patent: 3,717,647

Summary for Patent: 3,717,647